Transcatheter arterial chemoembolization and radiofrequency ablation in a joint venture with immunotherapy for hepatocellular carcinoma patients

Successive current trials using immune response checkpoint blockade, the systemic therapy for progressive hepatocellular carcinoma (HCC) has shifted dramatically towards targeting tumor microenvironment (TME). Locoregional therapies (LRTs) like radiofrequency ablation (RFA)/rhizotomy, trans-arterial chemoembolization (TACE) and surgical resection in initial stages are critical. LRTs perform crucial task of modulating system surrounding tumor, which is great importance prevailing era developing immuno-oncology treatments their direct effect on cells. Significant efforts needed exploring mechanisms latest combinational approach to boost clinical advantage with tolerable side effects. The present review highlights HCC followed by immunotherapeutic approaches HCC. Next, we discussed concealed given combination immunotherapy utilization practice.